Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Deffered Revenue: 2017-2018

Historic Non-Current Deffered Revenue for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2018 value amounting to $230,000.

  • Iovance Biotherapeutics' Non-Current Deffered Revenue fell 22.56% to $230,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $230,000, marking a year-over-year decrease of 22.56%. This contributed to the annual value of $230,000 for FY2018, which is 22.56% down from last year.
  • According to the latest figures from FY2018, Iovance Biotherapeutics' Non-Current Deffered Revenue is $230,000, which was down 22.56% from $297,000 recorded in FY2017.
  • Over the past 5 years, Iovance Biotherapeutics' Non-Current Deffered Revenue peaked at $297,000 during FY2017, and registered a low of $230,000 during FY2018.
  • Over the past 2 years, Iovance Biotherapeutics' median Non-Current Deffered Revenue value was $263,500 (recorded in 2017), while the average stood at $263,500.
  • Data for Iovance Biotherapeutics' Non-Current Deffered Revenue shows a maximum YoY decreased of 22.56% (in 2018) over the last 5 years.
  • Yearly analysis of 2 years shows Iovance Biotherapeutics' Non-Current Deffered Revenue stood at $297,000 in 2017, then dropped by 22.56% to $230,000 in 2018.